Mark Nedelman

Mark brings over 40 years of drug discovery and development experience to ANEWCRO, both as a client and veteran of the CRO industry. He has held leadership positions in academia (Massachusetts General Hospital), contributed to drug development in biopharma (Centocor and CeleCor Therapeutics), and led CRO industry efforts as GM at CRL and CEO of Ekam Imaging.

​

Previously, as CEO of Biomere, he developed and executed a strategy leading to its acquisition by Joinn Labs in 2019. Mark has co-authored over 50 peer-reviewed publications, three book chapters, and serves as a Trustee at Xenotherapeutics Foundation, a leading regenerative medicine non-profit.

April Hall

April Hall, Chief Business Officer, is a veteran of the CRO industry and a bioengineer by training. She has over 30 years of experience in pharmaceutical and medical device research. For the past 25 years, April focused on preclinical contract research business development. She served many leading contract labs including Charles River Laboratories, Transgenomics, Sinclair Research Center and Biomere/Joinn in this role. Her experience gives her a unique perspective supporting both sides of the development process, as a client herself developing devices and biologics as well as working with hundreds of clients to manage their preclinical programs globally. April’s diligence assures that our clients receive excellent responsiveness, quick study start times and services tailored to meet every need.